In this video Dr. Liptan explains the additive effects of CBD (cannabidiol) when taken with LDN (low dose naltrexone) in reducing neuroinflammation and fibromyalgia pain. CBD can also ease some of the side effects caused by LDN.
Approx. 20 Min
CBD for Fibro Pt 1
Dr. Liptan explains the science of CBD, and its uses in the treatment of fibromyalgia. This video also covers:
The difference between THC and CBD
The effects of CBD on the body based on human and animal studies
CBD’s benefits for pain, muscle tension, arthritis, anxiety, insomnia, and adrenal fatigue
For professional inquiries, please contact media@drliptan.com Affiliate links may be used above. When you make a purchase through an affiliate link, Dr. Liptan may be compensated a small percentage of the sale. Sales go toward supporting her channel.
___________________
**Comment**
I am not affiliated with any products nor do I make a red cent on anything related to this website or the support group; therefore, I can recommend the following product strictly from personal experience and use: Lidtke CBD Gold:https://lidtkecbd.com
We use the 2500mg plain. While it’s $189.00, I only take 2-6 drops at night. Definitely helps with sleep and pain.
Their CBD Gold line of tinctures blends the full-spectrum CBD extract with supplements such as iodine, GABA, 5-HTP, L-tryptophan, and a whole-food complex of the vitamin C component. Besides, the Lidtke brand indicates that their manufacturing process is from non-GMO, herbicide and pesticide-free hemp for those seeking assurance on the possibility of additives.
We also take LDN. You titrate up from 1.5mg. Our ending dose is 4.5mg but some patients need higher dosages. We found LDN helps our immune systems generally but specifically with better sleep and pain reduction.
Very informative documentary put out by the LDN Research Trust on Lyme/MSIDS. Dr. Horowitz, Dr. Toups, Dr. Schweig, Dr. Windham, Dr. Holtorf, & Dr. Schwarzback, speak on everything from testing, to diet, to inflammation, and how LDN can help patients.
Age-Related Differential Stimulation of Immune Response by Babesia microti and Borrelia burgdorferi During Acute Phase of Infection Affects Disease Severity.
Lyme disease is the most prominent tick-borne disease with 300,000 cases estimated by CDC every year while ~2,000 cases of babesiosis occur per year in the United States. Simultaneous infection with Babesia microti and Borrelia burgdorferi are now the most common tick-transmitted coinfections in the U.S.A., and they are a serious health problem because coinfected patients show more intense and persisting disease symptoms.B. burgdorferi is an extracellular spirochete responsible for systemic Lyme disease while B. microti is a protozoan that infects erythrocytes and causes babesiosis. Immune status and spleen health are important for resolution of babesiosis, which is more severe and even fatal in the elderly and splenectomized patients.
Therefore, we investigated the effect of each pathogen on host immune response and consequently on severity of disease manifestations in both young, and 30 weeks old C3H mice.
At the acute stage of infection, Th1 polarization in young mice spleen was associated with increased IFN-γ and TNF-α producing T cells and a high Tregs/Th17 ratio. Together, these changes could help in the resolution of both infections in young mice and also prevent fatality by B. microti infection as observed with WA-1 strain of Babesia. In older mature mice, Th2 polarization at acute phase of B. burgdorferi infection could play a more effective role in preventing Lyme disease symptoms. As a result, enhanced B. burgdorferi survival and increased tissue colonization results in severe Lyme arthritis only in young coinfected mice. At 3 weeks post-infection, diminished pathogen-specific antibody production in coinfected young, but not older mice, as compared to mice infected with each pathogen individually may also contribute to increased inflammation observed due to B. burgdorferi infection, thus causing persistent Lyme disease observed in coinfected mice and reported in patients.
Thus, higher combined proinflammatory response to B. burgdorferi due to Th1 and Th17 cells likely reduced B. microti parasitemia significantlyonly in young mice later in infection, while the presence of B. microti reduced humoral immunity later in infection and enhanced tissue colonization by Lyme spirochetes in these mice even at the acute stage, thereby increasing inflammatory arthritis.
___________________
**Comment**
Glad to see more work done on the polymicrobial nature of Lyme/MSIDS as most of us out here in Lyme-land struggle with numerous pathogens, not just Lyme (borrelia).
Key Quote: “Our findings recognize that microbial infections in patients suffering from TBDs do not follow the one microbe, one disease Germ Theory as 65% of the TBD patients produce immune responses to various microbes.”
Another problem:
83% of all commercial tests focus only on Lyme (borrelia), despite the fact we are infected with more than one microbe.
https://madisonarealymesupportgroup.com/2017/05/01/co-infection-of-ticks-the-rule-rather-than-the-exception/ Our study reveals high pathogen co-infection rates in ticks, raising questions about possible co-transmission of these agents to humans or animals, and their consequences to human and animal health. We also demonstrated high prevalence rates of symbionts co-existing with pathogens, opening new avenues of enquiry regarding their effects on pathogen transmission and vector competence.
Effective killing of Borrelia burgdorferi in vitro with novel herbal compounds
Kati Karvonen* and Leona Gilbert
Department of Biological and Environmental Science and Nanoscience Center, PO Box 35, FI-40014, University of Jyvaskyla, Finland
Abstract
Introduction: The tick-borne disease Lyme Borreliosis is caused by Borrelia bacteria. The disease can persist even after treatment with antibiotics, which is why other methods of treatment are needed. Herbal compounds and phytochemicals have been recently examined in relation to eradicating Borrelia bacteria in vitro.
Objective: The possible antimicrobial effect of two novel compounds, Biocidin Liquid and LSF Broad-Spectrum Liposomal formulas, was examined in the hopes of discovering an alternative method for eradication of Borrelia bacteria.
Methods: minimum inhibitory concentrations (MICs) and minimum bacterial deaths (MBDs), as well as, time-kill effect of each compound were utilized in the study.
Results: The Liquid formula effectively killed the spirochetes with 1:10 dilution, while the MIC for the Liposomal formula was 1:25. Moreover, the MIC for both compounds with Round Bodies was 1:50 and for biofilms 1:10. Though long-term effect (MBD) was seen only with 1:5 dilutions for both formulas. Additionally, the killing effect of each compound was observed already at 10 min post-treatment.
Conclusion: The study conducted here provides new insight into the antimicrobial effect of herbal compounds. Furthermore, studies such as these are required in order to discover possible alternatives to antibiotics in the battle against Borrelia infections.
___________________
**Comment**
The work was done in vitro(in a lab setting, not the human body) and funding was, “supported by Bio-Botanical research Inc. However, the authors devised the study design, collected and analyzed the data, and prepared the manuscript without input from the company. e decision to publish was the authors.”
Bio-botanical research manufactures Biocidin.
I’ve personally used Biocidin with no noticeable effects.
This work, similar to the in vitro work on stevia and essential oils still needs to be done in vivo (the human body) to determine it’s true effect, if any.
Personally, my husband and I have tried Stevia and EO’s internally. We relapsed on both. We also didn’t have any noticeable herx reactions. That isn’t to say they won’t work on someone else but for me and my husband we’ve ALWAYS responded to antibiotics with noticeable herxheimer reactions upon starting treatment.
Schizophrenia Linked with Abnormal Immune Response to Epstein-Barr Virus
01/09/2019
Credit: iStock
New research from Johns Hopkins Medicine and Sheppard Pratt Health System shows that people in the study with schizophrenia also have higher levels of antibodies against the Epstein-Barr virus (EBV), a herpes virus that causes infectious mononucleosis, so-called mono.
Researchers proposed two explanations for the association of heightened immune responses in patients with schizophrenia and EBV infection: schizophrenia might alter the immune systems of these patients and make them more susceptible to EBV, or EBV infection might increase the risk of schizophrenia.
“We are interested in the role of infectious agents such as Epstein-Barr virus in schizophrenia and other serious psychiatric disorders, so we did this study to look at the associations,” said Robert Yolken, M.D., the Theodore and Vada Stanley Distinguished Professor of Neurovirology in pediatrics at Johns Hopkins Children’s Center and senior author of the study. Yolken cautioned that the study wasn’t designed to determine cause and effect.
Schizophrenia is a mental disorder where patients have distorted thinking, perception, emotions, language, sense of self and behavior. According to the World Health Organization, schizophrenia affects more than 21 million people worldwide.
While schizophrenia has some genetic associations, genes that have been found to date explain only a portion of the disease risk. Environmental exposures, including to some infectious agents, have also been identified in previous studies as increasing the risk for schizophrenia.
EBV initially causes fever and swollen lymph nodes, and is commonly transmitted through oral contact such as kissing. In severe cases, it can spread to the central nervous system and cause persistent infection. Researchers wanted to see the relationship between this EBV infection and schizophrenia.
The researchers conducted a study among 743 people—432 with a schizophrenia diagnosis and 311 without a history of a psychiatric disorder to serve as a control group. Around 55 percent of the participants were men.
The researchers first measured levels of antibodies against components of EBV by comparing antibody levels in healthy people with those of people who have schizophrenia. They looked at the odds of having these antibodies in the 50th, 75th and 90th percentiles and found that people with schizophrenia were 1.7 to 2.3 times more likely to have increased levels of some EBV antibodies compared with people without schizophrenia.
Then they measured the antibodies to other related viruses such as varicella/chicken pox or herpes simplex type 1/cold sore virus, and didn’t find an increase of antibodies against these viruses in people with schizophrenia. These findings suggest that only EBV was associated with increased risk of schizophrenia.
After that, the researchers sequenced a portion of the participants’ DNA to determine their genetic risk for schizophrenia. Results from the analysis showed that people who had both evidence of increased genetic risk for schizophrenia and increased antibody levels to EBV had a more than eight times higher chance of being in the schizophrenia group as compared with controls. Approximately 10 percent of the individuals with schizophrenia had increased levels of both antibodies and genetic risk as compared with slightly more than 1 percent of the controls.
“We found that individuals with schizophrenia had an unusual response to Epstein-Barr virus,” said Yolken. “This indicated that the prevention and treatment of Epstein-Barr virus might represent an approach for the prevention and treatment of serious psychiatric disorders such as schizophrenia.”
Currently, there are no treatments available for EBV approved by the Food and Drug Administration, but a number of compounds that may prevent or treat replication of the virus are under investigation. The researchers considered the development of these approaches a high priority so that people with schizophrenia or other disorders associated with susceptibility to EBV could use them. In the meantime, researchers recommend preventing EBV transmission through good hygienic practices such as hand-washing and avoiding oral contact, such as kissing, with infected people.
The study is supported by the National Institute of Mental Health (MH-94268) and by the Stanley Medical Research Institute (07-1690).
Other authors on the study included Lorraine Jones-Brando of Johns Hopkins; Faith Dickerson, Cassie Stallings, Andrea Origoni, Emily Katsafanas, Kevin Sweeney and Sunil Khushalani from the Stanley Research Program at Sheppard Pratt; Glen Ford from VanPelt Biosciences; Giulio Genovese and Colm O’Dushlaine from Broad Institute of MIT and Harvard.
This press release is modified from a release prepared by Sheppard Pratt Health System.
A decade ago, Dr. Miyaoka accidentally discovered one. He treated two schizophrenia patients who were both institutionalized, and practically catatonic, with minocycline, an old antibiotic usually used for acne. Both completely normalized on the antibiotic.When Dr. Miyaoka stopped it, their psychosis returned. So he prescribed the patients a low dose on a continuing basis and discharged them.
Minocycline has since been studied by others. Larger trials suggest that it’s an effective add-on treatment for schizophrenia. Some have argued that it works because it tamps down inflammation in the brain. But it’s also possible that it affects the microbiome — the community of microbes in the human body — and thus changes how the immune system works.
https://madisonarealymesupportgroup.com/2017/10/03/treat-the-infection-psychiatric-symptoms-get-better/LLMD, Dr. Horowtiz, goes on record stating that antibiotics are effective in Schizophrenia. With irony he points out that the authors attribute the reason minocycline helped these patients is due to its ability to affect glutamate pathways in the CNS, blocking nitric oxide-induced neurotoxicity, and inflammation in the brain. He reminds them that minocycline is a tetracycline antibiotic that very well may be treating an infection. He also emphatically states that he has had several schizophrenic patients test positive for Bb, the agent of Lyme Disease. After taking doxycycline they improved significantly and with the help of their psychiatrist, were able to reduce and in some cases eliminate all of their antipsychotic medication. It is important to note that patients remained stable on antibiotics but their symptoms returned if they stopped treatment.
https://madisonarealymesupportgroup.com/2017/01/17/lymemsids-and-psychiatric-illness/In this presentation, Dr. Markes questions if psychiatric disorders are inflammatory diseases. She lists: Autism, Alzheimer’s, Schizophrenia, Bipolar, PTSD, Depression, Stress, Sleep Deprivation, Self-harm, and Suicide Attempts. She also describes a study in England observing children for over a decade in which children with a high IL-8 at age 8 have an 81% change of developing depression by age 18 and a 2-fold chance of becoming psychotic.
The first eight months of WWII with no fighting was called The Phoney War. Using millimetre waves as a fifth-generation or 5G wireless communications technology is a phoney war of another kind. 237 scientists from 43 countries consider 5G a threat to health, yet the UN’s Secretary General jokes about his ignorance on 5G, despite WHO reports going back almost two decades stating their harms. Read the article:http://www.greenmedinfo.com/slide/un-…
